anti-Spike IgG – Page 6 – Communicable Diseases Research

Immunoglobulin G1 Fc glycosylation as an early hallmark of severe COVID-19

심각한 COVID-19의 초기 특징인 면역글로불린 G1 Fc 글리코실화

Observational Study

Published on 2022-04-012022-09-11
Journal: EBioMedicine [Category] COVID19(2023년), MERS, SARS, 바이오마커, 유전자 메커니즘, 임상, 진단,

Characterization of Serum and Mucosal SARS-CoV-2-Antibodies in HIV-1-Infected Subjects after BNT162b2 mRNA Vaccination or SARS-CoV-2 Infection

BNT162b2 mRNA 백신 접종 또는 SARS-CoV-2 감염 후 HIV-1 감염 대상에서 혈청 및 점막 SARS-CoV-2-항체의 특성화

Article

Published on 2022-03-212022-09-11
Journal: Viruses [Category] SARS, 치료기술,

[키워드] all subject all subjects analysed Anti-spike anti-Spike IgG antibody Antiretroviral therapy BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine characterization convalescent detectable dose ELISA Frequency HIV-1 humoral humoral immune response IgA IgA antibodies IgA antibody IgG immune Immunity immunogenicity indicate induce investigated mRNA vaccination mRNA vaccine mucosal mucosal immunity neutralization activity Neutralization assay Neutralizing activity Neutralizing antibodies neutralizing antibody neutralizing capacity no significant difference of BNT162b2 Patient patients Saliva saliva samples SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike-specific SARS-CoV-2-specific antibodies SARS-CoV-2-specific antibody serum serum levels significantly higher significantly lower specific antibodies spike IgA spike-specific antibody response subject subjects uninfected vaccination Vaccine vaccine response vaccinee vaccinees while
[DOI] 10.3390/v14030651 PMC 바로가기 [Article Type] Article

Durability of Anti-Spike Antibodies in Infants After Maternal COVID-19 Vaccination or Natural Infection

산모의 COVID-19 백신 접종 또는 자연 감염 후 유아에서 스파이크 방지 항체의 내구성

Multicenter Study

Published on 2022-03-152022-09-12
Journal: JAMA [Category] MERS, 진단,

[키워드] anti-Spike IgG COVID-19 Infant infected with COVID-19 Maternal mother natural persistence
[DOI] 10.1001/jama.2022.1206 PMC 바로가기 [Article Type] Multicenter Study

Evolution of anti-SARS-CoV-2 immune response in a cohort of French healthcare workers followed for 7 months

프랑스 의료 종사자 집단에서 7개월 동안 추적한 항 SARS-CoV-2 면역 반응의 진화

Article

Published on 2022-03-012022-09-11
Journal: Infectious diseases now [Category] MERS, SARS, 진단, 치료기술, 치료법,

Seroprevalence of SARS-Cov-2 IgG antibodies in patients at a single center in Saudi Arabia

사우디 아라비아의 단일 센터에서 환자에서 SARS-Cov-2 IgG 항체의 혈청 유병률

Article

Published on 2022-03-012022-09-12
Journal: Annals of Saudi medicine [Category] MERS, SARS, 진단,

[키워드] acute respiratory syndrome age All participant anti-Spike IgG antibody applied Blood BMI body mass index Care clinics conflict coronavirus coronavirus disease COVID-19 COVID-19 disease COVID-19 pandemic COVID-19 patient diagnosed with COVID-19 enzyme-linked immunosorbent assay female gender Follow-up visit groups help IgG anti-spike antibody IgG antibody individual Infection interquartile median multivariate analyses multivariate logistic regression outcome pandemic participant Patient positive Prevalence public health public health measure reflect Sample SARS CoV-2 SARS-CoV-2 Saudi Arabia seropositive seropositive individual Seropositivity Seroprevalence serum samples Sex single center single-center study subject subjects Tertiary understanding was used
[DOI] 10.5144/0256-4947.2022.69 PMC 바로가기 [Article Type] Article

Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2

SARS-CoV-2에 노출되거나 노출되지 않은 의료 종사자의 시간 경과에 따른 BBIBP-CorV 백신에 대한 체액 반응

Clinical Trial

Published on 2022-03-012022-09-12
Journal: Molecular immunology [Category] MERS, SARS, 임상, 진단,

[키워드] age Analysis analyzed anti-spike antibodies anti-Spike IgG antibody antibody concentration Antibody Response Antibody titer BBIBP-CorV both group Combination dose event healthcare worker highest humoral Humoral response immune protection increase in individual Linear regression model magnitude memory B multivariable naïve subject participant persistence produced SARS-CoV-2 SARS-CoV-2 infected individual SARS-COV-2 infection second dose sequence significant increase significantly significantly higher single dose Sinopharm subject subjects T cell responses the vaccine vaccination Vaccine women younger subject
[DOI] 10.1016/j.molimm.2022.01.009 PMC 바로가기 [Article Type] Clinical Trial

Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study

Observational Study

Published on 2022-03-012022-10-05
Journal: The Lancet. Healthy longevity [Category] COVID19(2023년), SARS, 임상, 진단,

[키워드] Abstract Administered administration age anti-RBD Anti-RBD IgG anti-Spike IgG Anti-spike IgG responses antibody Antibody Response antigenicity automated baseline binding antibody unit blood sample BNT162b2 BNT162b2 vaccine boost Canada Care clinical clinically Cohort cohorts collected combinations Comorbidity Concentration COVID-19 COVID-19 mRNA Vaccination COVID-19 vaccine decrease distribution dose doses Effectiveness eligible ELISA enrolled extended-interval first dose fluctuation for inclusion force French Government Heterologous heterologous prime-boost homologous or heterologous individual infected individual Interim Interim report log material Moderna mRNA vaccine mRNA vaccines mRNA-1273 mRNA-1273 vaccine mRNA-based COVID-19 vaccine nucleocapsid protein of BNT162b2 Older participant Participants Pfizer-BioNTech prime and boost prospective observational cohort PROTECT Public reference response SARS-COV-2 infection SARS-CoV-2-specific IgG second dose serological response service significant difference significant increase tested the receptor-binding domain the spike protein timepoint translation Trimeric spike protein university Vaccine vaccine availability vaccine dose Vaccines was done were used
[DOI] 10.1016/S2666-7568(22)00012-5 PMC 바로가기 [Article Type] Observational Study

Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan

Article

Published on 2022-02-172022-10-28
Journal: Vaccines [Category] COVID-19,

[키워드] 95% CI Administered age analyzed anti-RBD Anti-RBD IgG anti-Spike IgG anti-spike IgG level Asian Asian populations body weight boost ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine clinically correlated COVID-19 D-dimer level death declined elicited enrolled fatigue female Fever geometric mean concentration GMC GMCs group Humoral immunity immunogenicity Neutralizing antibody titer Pain participant Platelet Platelet count Population reactogenicity receive recipient recipients response robust SARS-CoV-2 SARS-CoV-2 antibodies Serious Adverse Event seroconversion rate significantly Standard statistically Taiwan vaccination Vaccine
[DOI] 10.3390/vaccines10020312 PMC 바로가기 [Article Type] Article

Anti-SARS-CoV-2 IgA Identifies Asymptomatic Infection in First Responders

Anti-SARS-CoV-2 IgA, 최초 응답자의 무증상 감염 식별

Article

Published on 2022-02-152022-09-11
Journal: The Journal of Infectious Diseases [Category] MERS, 진단, 치료법,

[키워드] added anti-Nucleocapsid IgG Anti-spike anti-Spike IgG antibody Asymptomatic asymptomatic infection baseline benefit correlated COVID-19 cumulative cumulative incidence emergency medical service Epidemiology estimates exposure to First responder first responders Follow-up General population group high risk IgA IgG illness illnesses immune response Immunoglobulin immunoglobulin A IMPROVE incidence infection with SARS-CoV-2 longitudinal majority medical service police positive provided Responder retrospective risk SARS-CoV-2 SARS-COV-2 infection serologic surveys serologic test serologic tests seropositive Serosurvey Serosurveys spike IgA were assessed with COVID-19
[DOI] 10.1093/infdis/jiab524 PMC 바로가기 [Article Type] Article

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

브라질에서 코로나 박 코비드 -19 백신의 이전 수용자 (RHH-001)의 이전 수용자에서 이종과 동종 코비드 -19 부스터 백신 접종

Clinical Trial

Published on 2022-02-052022-08-13
Journal: Lancet (London, England) [Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, 임상, 진단, 치료기술,

[키워드] 95% CI Ad26 Ad26.COV2-S Ad26.COV2-S vaccine Administered administration adverse events age All participant All participants anti-Spike IgG anti-spike IgG antibodies Anti-spike IgG antibody anti-spike IgG response Anti-spike IgG responses Antibody concentrations assigned AstraZeneca AZD1222 B.1.1.529 B.1.617.2 baseline binding blind BNT162b2 boost booster booster dose booster vaccination Booster vaccine Brazil ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine Concentration CoronaVac COVID-19 COVID-19 vaccine detectable discharged home dose eligible ENhance except for finding FIVE for inclusion four groups funding geometric geometric mean geometric mean ratio geometric mean ratios group Heterologous homologous homologous booster responses IgG antibody IgG responses immune response immune responses immunogenicity IMPROVE inactivated Infection inferiority janssen Live virus neutralising antibodies Local local and systemic reactogenicity profiles Ministry of Health mRNA vaccine Neutralising Antibodies neutralising antibody neutralising antibody titre neutralising antibody titres non-inferiority non-inferiority margin Older Older adults Omicron variant Omicron variants outcome participant Pfizer Pfizer–BioNTech phase 4 primary analysis Primary outcome profiles pseudovirus neutralising antibodies randomisation randomised Randomly reached recipient recombinant adenoviral vectored vaccine recombinant adenoviral-vectored ChAdOx1 nCoV-19 vaccine regimen Registered RHH-001 robust secondary Secondary outcomes Serious Adverse Events Seropositivity significant increase Sinovac stratified systemic reactogenicity the vaccine Vaccine vectored vaccine virus neutralising antibody whole-virion SARS-CoV-2 vaccine
[DOI] 10.1016/S0140-6736(22)00094-0 PMC 바로가기 [Article Type] Clinical Trial